Active Biotech AB Stock Xetra
Equities
BTPC
SE0001137985
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Jul. 01 | Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis | CI |
May. 22 | Active Biotech Secures Exclusive Licensing Rights to Multiple Myeloma Drug | MT |
Sales 2024 * | - | Sales 2025 * | 15.6M 1.48M 1.36M | Capitalization | 183M 17.32M 15.9M |
---|---|---|---|---|---|
Net income 2024 * | -42M -3.98M -3.66M | Net income 2025 * | -35M -3.32M -3.05M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.39% |
Managers | Title | Age | Since |
---|---|---|---|
Helén Tuvesson
CEO | Chief Executive Officer | 62 | 97-12-31 |
Hans Kolam
DFI | Director of Finance/CFO | 73 | 99-12-31 |
Erik Vahtola
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
BRD | Director/Board Member | 74 | 19-05-22 |
Director/Board Member | 50 | 19-12-31 | |
Michael Shalmi
CHM | Chairman | 59 | 19-05-22 |
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- ACTI Stock
- BTPC Stock